MMSI MERIT MEDICAL SYSTEMS INC

Nasdaq Surgical & Medical Instruments & Apparatus UT CIK: 0000856982
AI RATING
BUY
72% Confidence

Investment Thesis

Merit Medical demonstrates solid fundamental business quality with 11.8% revenue growth, 48.4% gross margins, and a fortress balance sheet featuring 5.08x current ratio and conservative 0.45x leverage. However, returns on capital remain concerning with 2.5% ROE and 1.5% ROA, while net income growth (6.8% YoY) significantly lags revenue growth, signaling operational efficiency challenges that require resolution.

Strengths

  • + Double-digit revenue growth (11.8% YoY) with positive net income growth (6.8% YoY) in medical device sector
  • + Exceptional liquidity position with 5.08x current ratio and $488.1M cash against conservative 0.45x debt-to-equity ratio
  • + Strong gross margin of 48.4% indicates pricing power and product quality; positive free cash flow generation of $24.7M
  • + Interest coverage of 5.5x and moderate capex of $16.0M demonstrate disciplined capital allocation

Risks

  • ! Dangerously low returns on equity (2.5%) and assets (1.5%) indicate severe capital efficiency problems or over-capitalization
  • ! Margin compression evident as revenue growth (11.8%) significantly outpaces net income growth (6.8%), suggesting operating leverage issues
  • ! Operating margin of 11.6% is materially below gross margin of 48.4%, pointing to elevated operating expenses relative to gross profit generation
  • ! Long-term debt of $735.2M exceeds cash position by $247.1M, requiring ongoing debt service and deleveraging discipline

Key Metrics to Watch

Financial Metrics

Revenue
381.9M
Net Income
41.0M
EPS (Diluted)
$0.68
Free Cash Flow
24.7M
Total Assets
2.7B
Cash
488.1M

Profitability Ratios

Gross Margin 48.4%
Operating Margin 11.6%
Net Margin 10.7%
ROE 2.5%
ROA 1.5%
FCF Margin 6.5%

Balance Sheet & Liquidity

Current Ratio
5.08x
Quick Ratio
3.46x
Debt/Equity
0.45x
Debt/Assets
40.2%
Interest Coverage
5.49x
Long-term Debt
735.2M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-06T18:17:31.046109 | Data as of: 2026-03-31 | Powered by Claude AI